David Gollaher Net Worth

David Gollaher biography

Dr. David L. Gollaher Ph.D. serves as Independent Director of the Company. Dr. Gollaher is currently the Head of Policy and Government Affairs at Vir Biotechnology, Inc., a public immunology company focused on infectious diseases. From February 2014 to June 2018, he served as Vice President of Global Government Affairs and Policy at Gilead Sciences, Inc., a public biopharmaceutical company. From September 1993 through January 2014, Dr. Gollaher was co-founder and Chief Executive Officer of the California Healthcare Institute (CHI). In 2018, Dr. Gollaher was appointed Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. He currently serves on the Board of Overseers for Scripps Research . Earlier in his career, Dr. Gollaher was vice president at Scripps Clinic and Research Foundation, responsible for managed care, strategy and corporate affairs. He earned his B.A. from the University of California Santa Barbara and his master’s and Ph.D. degrees, concentrating in the history of science and medicine, from Harvard Un diversity.

What is the salary of David Gollaher?

As the Independent Director of Cidara Therapeutics Inc, the total compensation of David Gollaher at Cidara Therapeutics Inc is $55,697. There are 10 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.

How old is David Gollaher?

David Gollaher is 70, he's been the Independent Director of Cidara Therapeutics Inc since 2018. There are no older and 17 younger executives at Cidara Therapeutics Inc.

What's David Gollaher's mailing address?

David's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.

Insiders trading at Cidara Therapeutics Inc

Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio... и Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.

What does Cidara Therapeutics Inc do?

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.

Cidara Therapeutics Inc executives and stock owners

Cidara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jeffrey Stein,
  President, Chief Executive Officer, Director
• Dr. Jeffrey L. Stein Ph.D.,
  Pres, CEO & Exec. Director
• Neil Abdollahian,
  Chief Business Officer
• Taylor Sandison,
  Chief Medical Officer
• Paul Daruwala,
  Chief Operating Officer
• Dr. Taylor Sandison,
  Chief Medical Officer
• Daniel Burgess,
  Independent Chairman of the Board
• Theodore Schroeder,
  Independent Director
• Chrysa Mineo,
  Independent Director
• Timothy Franson,
  Independent Director
• David Gollaher,
  Independent Director
• Robert Uhl,
  IR Contact Officer
• Jessica Oien,
  General Counsel, Secretary
• James Levine,
  Chief Financial Officer
• Dr. Kenneth F. Bartizal Ph.D.,
  Chief Devel. Officer
• Allison Lewis CCP, SPHR,
  VP of HR
• Shane M. Ward,
  Chief Legal Officer & Corp. Sec.
• Christopher A. Kurtz,
  Exec. VP of Technical Operations
• Brady Johnson,
  Principal Accounting Officer, Controller & VP of Fin.
• Paul Daruwala,
  COO & Chief Commercial Officer
• Dr. Preetam Shah M.B.A., Ph.D.,
  CFO & Chief Bus. Officer
• Dr. Kevin M. Forrest Ph.D.,
  Founder and Chief Strategy Officer
• Robert J Perez,
  Director
• Scott M Rocklage,
  Director
• Ken Bartizal,
  Chief Development Officer
• Matthew Onaitis,
  Gnrl Counsel, CFO & Secretary
• Marc Wilson,
  Chief Accounting Officer
• Dirk Thye,
  Chief Medical Officer
• Kevin Forrest,
  COO & CFO
• Laura Tadvalkar,
  Director
• Preetam Shah,
  CFO & CBO
• Target N Vbb Biotech Ag Bio...,
  
• Patrick J Heron,
  Director
• Nina S Kjellson,
  Director
• Steve Elms,
  Director
• Bonnie L Bassler,
  Director
• Carin Canale Theakston,
  Director
• Leslie Tari,
  CHIEF SCIENTIFIC OFFICER
• Brady Johnson,
  Vice President, Finance
• Shane Ward,
  COO & CLO
• Ryan Spencer,
  Director
• James Merson,
  Director
• Capital Management, L.P.Ra ...,